Highlights Sep 21 - Sep 27, 2026
new every Sunday
This week brought a renewed federal scheduling push alongside clinical expansion into depression and borderline personality disorder. New animal data, safety guidance, and an investigation of a veteran psychedelic church also highlighted the field's unresolved evidence and risk questions.
-
01
DEA renews effort to place five psychedelic tryptamines in Schedule I as FDA research progress draws criticism from advocates
The DEA's renewed bid to schedule five tryptamines could constrain research, including a 4-OH-DiPT program for postpartum depression.
-
02
Draulio Araújo on the path from ayahuasca research to controlled DMT trials for treatment-resistant depression
Araújo charts the path from ayahuasca findings to a 140-person DMT depression trial designed to better address psychedelic blinding.
-
03
Psilocybin may help the brain recover from repeated concussion, but evidence remains limited to animal research
A rat study found post-concussion psilocybin altered vascular, connectivity, tau, and BDNF markers, but human relevance is unknown.
-
04
A Phase 1 trial tests psilocybin for borderline personality disorder while keeping dialectical behavior therapy in place
A new Phase 1 trial will add two 25 mg psilocybin doses to ongoing DBT for 18 carefully screened adults with borderline personality disorder.
-
05
Clay Martin, psilocybin, and the Path of the Barbarian Spirit: A veteran’s violent pagan psychedelic church
An investigation shows how a veteran psilocybin church blends trauma healing and community with violent mythology and extremist politics.
-
06
After an Ayahuasca Retreat: Research-Based Answers to Questions About Integration, Difficulties, Grounding, Community and Help
This evidence-based guide pairs post-ayahuasca grounding advice with warning signs for seeking help and candor about limited integration research.